SCHEMBL39756

SCHEMBL39756

CC(C)(C)OC(=O)N1CCN(CCO)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48
CHRM1 P11229 1/20 0.48
CHRM3 P20309 1/20 0.48
NR1H2 P55055 1/20 0.45
ACKR3 P25106 2/20 0.44
HPGD P15428 1/20 0.44
EPHX2 P34913 1/20 0.43
TLR8 Q9NR97 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RECQL P46063 1/20 0.42
EPHX1 P07099 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1920985 0.94 MEN1 (0.48) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL2358459 0.92 USP2 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL8242595 0.91 USP2 (0.61) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL18928825 0.90 USP2 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL214593 0.90 USP2 (0.49) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1730281 0.89 SMN1; SMN2 (0.43) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL12193455 0.88 USP2 (0.47) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL20873847 0.87 USP2 (0.53) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL24745371 0.87 CNR1 (0.45) USP2SMN1; SMN2CHRM2CHRM4CHRM1
SCHEMBL1715344 0.87 USP2 (0.46) USP2SMN1; SMN2CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1024 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118087082-B High-strength cellulose acetate blend fiber fabric and dyeing process thereof 浙江爱利斯染整有限公司 2025-02-18 CN claimed
CN-118087082-A High-strength cellulose acetate blend fiber fabric and dyeing process thereof 浙江爱利斯染整有限公司 2024-05-28 CN claimed
CN-117265880-B Smooth and crease-resistant T/C fabric and preparation method thereof 东莞市玩乐童话婴儿用品有限公司 2024-04-26 CN claimed
CN-117447424-A Preparation method of 1-Boc-4- (2-chloroethyl) piperazine 安徽昊帆生物有限公司 2024-01-26 CN claimed
CN-117265880-A Smooth and crease-resistant T/C fabric and preparation method thereof 东莞市玩乐童话婴儿用品有限公司 2023-12-22 CN claimed
CN-116178308-A Crocetin derivative and pharmaceutical application thereof 南京艾德凯腾生物医药有限责任公司 2023-05-30 CN claimed
US-9399635-B2 Pyrazole derivative GREEN TECH CO., LTD. (JP) 2016-07-26 US claimed
US-20140088029-A1 NOVEL PYRAZOLE DERIVATIVE PHARMA EIGHT CO., LTD. (JP) 2014-03-27 US claimed
US-20260144788-A1 COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF UBIX THERAPEUTICS, INC. (KR) 2026-05-28 US disclosed
EP-4747235-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 EP disclosed
EP-4743465-A1 BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-20 EP disclosed
EP-3972649-B1 MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE NOVARTIS AG (CH) 2026-05-13 EP disclosed
CN-116323601-B 2- (3-Pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl) -acetamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors 阿戈麦布西班牙股份有限公司 2026-05-12 CN disclosed
EP-4735438-A2 HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS Merck Patent GmbH (DE) 2026-05-06 EP disclosed
EP-0859607-A1 GUANIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1998-08-26 EP disclosed
US-5792769-A POTENT ANTICOAGULANT, ANTIINFLAMMATORY AGENT; TREATMENT/PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS, VASCULAR SYSTEM DISORDERS, ANTITUMOR AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1998-08-11 US disclosed
EP-0839805-A1 Pyrrolidinone derivatives and their use as antipsychotic medicaments MITSUI TOATSU CHEMICALS, INC. (JP) 1998-05-06 EP disclosed
WO-1997024135-A1 AMIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1997-07-10 WO disclosed
WO-1997011693-A1 GUANIDINO PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 1997-04-03 WO disclosed
US-4247549-A Piperazine-1-carboxylic acid esters possessing antidepressant or analgesic activity ICI AMERICAS INC. (US) 1981-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144788-A1 COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF PTPN6, PTPN1, PTPN11 USP2 762/4885SMN1; SMN2 2201/4885CHRM2 4793/4885
US-20140088029-A1 NOVEL PYRAZOLE DERIVATIVE PSEN2, MAPT, PSEN1 USP2 3381/4885SMN1; SMN2 1138/4885CHRM2 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.